// AI in discovery · Research labs and data

Life Sciences Radar

The radar compares what 25 large pharma and biotech R&D spenders say in public about two things: AI and computation in drug discovery, and the digitalisation of their research labs and scientific data. Each company gets two scores for each theme. Priority is how much weight the company puts on the theme in its own disclosures, on a scale of 1 to 10. Delivery is how far its published evidence shows the work running, from 0 to 10. Open any company to see the quotes and links behind its scores.

Beside the scores sits observed activity: commitments the company made public in the last 12 months, such as partnerships, compute and new research units, and the R&D roles open on its job site on 6 October 2026. Activity is a count of public signals, not a score, and it never changes Priority or Delivery. A company with fresh commitments and open roles but a low Delivery score is one to look into.

The scores come only from public information published up to 5 October 2026. They are Ortent's assessment and have not been independently validated. A low score can mean a company says little in public, or that we could not reach some of its sources, so the coverage status sits next to every score. If you know of public information we missed, report it at the foot of the page and we will review it at the next quarterly refresh.

25 companiesEvidence to 5 Oct 2026Job sites read 6 Oct 2026Refreshed quarterlyOctober 2026 editionRead the method
Theme
Sort by
Priority Delivery Delivery claimed, not evidenced Provisionala company document could not be read in full new · rolescommitments made public in the last 12 months · R&D roles open on 6 Oct
CompanyP / DActivity
Rochescaled
Priority 8 / Delivery 7
Observed activity: 4 new · 24 roles

Priority 8: what the company says

Revolutionizing drug R&D with Lab-in-a-Loop Aviv Regev, Head of Genentech Research and Early Development (gRED)
Roche Pharma Day 2026 presentation, 28 Sep 2026, p. 5
Our ‘R&D Excellence’ initiative, launched two years ago to accelerate our research and development, is showing strong progress.
Roche Annual Report 2025, 29 Jan 2026, p. 12
Evolve our R&D engine and invest in its excellence Ongoing R&D investments Boston Innovation Center focusing on CVRM and AI in drug development opened
Roche Pharma Day 2026 presentation, 28 Sep 2026, p. 62

Delivery 7, scaled: what it shows running

Pathobiology maps have scaled and accelerated our pipeline Example: IBD pathobiology maps
Roche Pharma Day 2026 presentation, 28 Sep 2026, p. 76
BRAID (biology AI) PrescientDesign (antibodies AI) gRED Computational Sciences (gCS) consolidated ... Recursion collaboration ... NVIDIA partnership OpenAI pilot partnership AI factory (NVIDIA)
Roche Pharma Day 2026 presentation (London, 28 September 2026), 28 Sep 2026, p. 71
AI-enhanced pathobiology maps across our TAs ... +155% First map deployed (IBD) 4 neurology maps deployed increase in LI entries in 2 years
Roche Pharma Day 2026 presentation, 28 Sep 2026, p. 77

Commitments made public in the last 12 months: 4

Prior 12 months: 2. Search coverage: partial.

R&D roles open on 6 Oct 2026: 24

and 18 more in the company brief.

Technology named in these postings

Named as in use: AWS, Kubernetes, Terraform, PyTorch

Asked for as experience: Helm, LangGraph

Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Roche lists every source.

Eli Lillylive
Priority 8 / Delivery 4
Observed activity: 6 new · 12 roles

Priority 8: what the company says

We pursued breakthrough discoveries on three fronts. ... Partnerships were forged to deploy AI to help decode biology, with the potential to accelerate the discovery of new treatments
Eli Lilly and Company 2026 Proxy Statement (DEF 14A), incl. shareholder letter and CD&A, 20 Mar 2026
today announced it is building the most powerful supercomputer owned and operated by a pharmaceutical company, in collaboration with NVIDIA
Lilly partners with NVIDIA to build the industry's most powerful AI supercomputer, supercharging medicine discovery and delivery for patients, 28 Oct 2025
The supercomputer is the world's first NVIDIA DGX SuperPOD with DGX B300 systems. It is powered by more than 1,000 B300 GPUs on a unified networking fabric
Lilly partners with NVIDIA to build the industry's most powerful AI supercomputer, 28 Oct 2025

Delivery 4, live: what it shows running

Launched a platform, giving biotechnology companies access to artificial intelligence (AI)-enabled drug discovery models.
Eli Lilly and Company 2026 Proxy Statement (DEF 14A), incl. shareholder letter and CD&A, 20 Mar 2026
Lilly TuneLab, which together support biotech innovation by providing access to strategic capital, lab space and technology, and research and development capabilities including advanced AI models.
Lilly announces plans to open Lilly Gateway Labs site in Philadelphia, 19 Nov 2025
Lilly TuneLab, an AI and machine learning platform, provides biotech companies with access to select Lilly models for drug discovery built on decades of Lilly's proprietary data.
NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery in the Age of AI, 12 Jan 2026

Commitments made public in the last 12 months: 6

Prior 12 months: 6. Search coverage: partial.

R&D roles open on 6 Oct 2026: 12

and 6 more in the company brief.

Technology named in these postings

Named as in use: Lilly TuneLab, Hamilton, Tecan, Opentrons, LillyPod (NVIDIA Blackwell Ultra SuperPOD)

Asked for as experience: AWS, PyTorch, NVIDIA GPU infrastructure

Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Eli Lilly lists every source.

Novo Nordisklive
Priority 8 / Delivery 4
Observed activity: 4 new · 2 roles

Priority 8: what the company says

Key research & development enablers ... End-to-end AI ... and data science
Capital Markets Day 2026: R&D strategy (Lange, Patel), 21 Sep 2026, p. 3
Significant changes in our R&D set-up ... and AI capabilities to deliver at quality ... and pace
Capital Markets Day 2026: R&D strategy (Lange, Patel), 21 Sep 2026, p. 14
External innovation is a key enabler to expand the pipeline and strengthen competencies in AI ... Partnering with leading AI providers
Capital Markets Day 2026: Corporate strategy presentation, 21 Sep 2026, p. 12

Delivery 4, live: what it shows running

AI is leveraged to improve speed, success and productivity across the research & development value chain Select achievements in 2026
Capital Markets Day 2026: R&D strategy presentation, 21 Sep 2026, p. 7
Pre-clinical asset identified with key outputs ... Combine human-designed sequences with ML-assisted design in an ... active-learning loop
Capital Markets Day 2026: R&D strategy (Lange, Patel), 21 Sep 2026, p. 8
Novo Nordisk and AWS have created a co-innovation hub in London ... to compress the path from drug target to first human dose ... a dedicated co-innovation hub within our existing facility in London
Novo Nordisk and AWS enter strategic partnership to accelerate drug discovery through AI, 10 Aug 2026

Commitments made public in the last 12 months: 4

Prior 12 months: 6. Search coverage: partial.

Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Novo Nordisk lists every source.

AstraZenecascaled
Priority 7 / Delivery 6
Observed activity: 5 new · 6 roles

Priority 7: what the company says

we are investing significantly in transformative technologies that will shape the future of medicine ... This includes harnessing the power of AI where, for example, 90% of our small molecule discovery pipeline is already AI-assisted
AstraZeneca Annual Report & Form 20-F Information 2025, 18 Feb 2026, p. 7
Our $2.5 billion investment expands early discovery and development and incorporates an AI and data science laboratory.
AstraZeneca Annual Report & Form 20-F Information 2025, 18 Feb 2026, p. 7
In R&D, we are developing an ecosystem of foundation models and AI agentic frameworks to accelerate our drug discovery
AstraZeneca Annual Report & Form 20-F Information 2025, 18 Feb 2026, p. 38

Delivery 6, scaled: what it shows running

Over 90% of our small molecule discovery pipeline is AI-enabled, with similar approaches actively applied to other areas, including biologics.
AstraZeneca Annual Report & Form 20-F Information 2025, 18 Feb 2026, p. 38
>90% of our small molecule discovery pipeline is enabled by AI
AI & data in Drug Discovery & R&D (corporate R&D page), Aug 2026
Delivered industry-leading genomic insights while remaining sustainable, redesigning algorithms that cut CO2 emissions and compute time by 99.8% compared to global standards.
AstraZeneca Annual Report & Form 20-F Information 2025, 18 Feb 2026, p. 30

Commitments made public in the last 12 months: 5

Prior 12 months: 3. Search coverage: partial.

R&D roles open on 6 Oct 2026: 6

Technology named in these postings

Named as in use: AWS, Claude Code, Claude Cowork, Confluence, Domino, GitHub, GitHub Copilot, Hugging Face, Kubernetes, M365 Copilot, NVIDIA DGX SuperPOD

Asked for as experience: GitHub Actions

Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for AstraZeneca lists every source.

Bristol Myers Squibbscaled
Priority 7 / Delivery 6
Observed activity: 6 new · 4 roles

Priority 7: what the company says

Our focus on innovation includes leveraging data and integrating AI across the business to become a more efficient organization and accelerate the delivery of medicines to patients.
Bristol Myers Squibb 2026 Proxy Statement, 25 Mar 2026, p. 3
all of our small molecule experiments and half of our large molecule experiments are now using an AI model to predict probability of success
Bristol Myers Squibb 2026 Proxy Statement, 25 Mar 2026, p. 3
today announced it will expand its compute infrastructure to deploy an NVIDIA DGX SuperPOD with DGX Vera Rubin NVL72 systems
Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA, 20 Jul 2026

Delivery 6, scaled: what it shows running

builds on nearly three years of collaboration that began when BMS first deployed NVIDIA DGX SuperPOD infrastructure to support its Research and Development activities
Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA, 20 Jul 2026
all of our small molecule experiments and half of our large molecule experiments are now using an AI model to predict probability of success
Bristol Myers Squibb 2026 Proxy Statement, 25 Mar 2026, p. 3
AI informs the design of every small molecule program and the majority of the company’s large molecule programs
Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA, 20 Jul 2026

Commitments made public in the last 12 months: 6

Prior 12 months: 3. Search coverage: partial.

R&D roles open on 6 Oct 2026: 4

Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Bristol Myers Squibb lists every source.

Daiichi Sankyolive
Priority 7 / Delivery 4
Observed activity: 1 new · 1 role

Priority 7: what the company says

Identify next BGTs by 2030 ... 当社は、2030年までに次世代のBGTsを特定することを重要な戦略目標として位置づけております。 ... 国内外の研究拠点の拡充やAI・データ駆動型創薬の推進

[Ortent translation: We have set identifying next-generation BGTs by 2030 as an important strategic goal. ... expanding our research sites in Japan and overseas and advancing AI and data-driven drug discovery]

有価証券報告書 第21期 (Annual Securities Report FY2025, 1 Apr 2025-31 Mar 2026), 19 Jun 2026, p. 12
Expanding Drug Discovery Research Capabilities: ... Expanding and strategizing AI-driven drug discovery into multi-modality research ... AI-driven molecular design
FY2025 Financial Results and 5-Year Business Plan Presentation & Discussion (FY2026-FY2030), 11 May 2026, p. 69
Smart Lab: Enabling Competitive AI-driven Drug Discovery ... Seamless data feedback to molecular design AI ... Smart Lab is the cornerstone of AI-driven drug design success.
Science & Technology Day 2025, 16 Dec 2025, p. 85

Delivery 4, live: what it shows running

OpenFold-3をはじめとする最先端のAIモデルを社内環境に導入し、研究者が利用できるアプリケーションとしてクラウド環境上で提供しています。

[Ortent translation: We have brought state-of-the-art AI models, starting with OpenFold-3, into our internal environment and provide them in the cloud as applications our researchers can use.]

DX - データと先進デジタル技術の活用 (DX corporate page), No printed date. Its content dates it to Jul 2026 or later, and we read it on 6 Oct 2026
大規模言語モデルによるヒト遺伝子データの分析 複雑で膨大な遺伝子情報を高性能Graphics Processing Unit(GPU)で処理し

[Ortent translation: Analysis of human genetic data with large language models. Complex and vast genetic information is processed on high-performance graphics processing units (GPUs) and]

DXを継続的に動かす基盤と体制 (DX enablers page), No printed date. Its content dates it to May 2026 or later, and we read it on 6 Oct 2026
AIエージェントをバイオインフォマティクス業務に導入し、生命科学データの探索・解析を効率化・高度化しています。実際のデータ解析業務を通じてその有用性を検証し

[Ortent translation: We have introduced AI agents into bioinformatics work, making the exploration and analysis of life science data more efficient and more advanced. We are testing their usefulness through real data analysis work and]

DX - データと先進デジタル技術の活用 (DX corporate page), No printed date. Its content dates it to Jul 2026 or later, and we read it on 6 Oct 2026

Commitments made public in the last 12 months: 1

Prior 12 months: 2. Search coverage: partial.

R&D roles open on 6 Oct 2026: 1

Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Daiichi Sankyo lists every source.

Regeneronlive
Priority 7 / Delivery 4
Observed activity: 0 new · 3 roles

Priority 7: what the company says

We aim to complete sequencing of 10 million samples and integrate AI and big data tools to improve drug discovery and digital health solutions by 2030.
2025 Responsibility Report, 28 Apr 2026, p. 17
through the Regeneron Genetics Center ... we’re committing to sequencing 10 million samples and integrating artificial intelligence (AI) and big data tools to advance drug discovery
Responsibility at Regeneron: A Look Back and a Look Ahead (story), 28 Apr 2026
SCIENCE-LED 2030 GOALS WILL HOLD US ACCOUNTABLE ... Completing sequencing of 10M samples and integrating AI and big data tools to improve drug discovery
Regeneron Corporate Presentation, July 2026, Jul 2026, p. 31

Delivery 4, live: what it shows running

We use innovative technologies, such as machine learning, to sequence exomes, align with health information and perform large-scale analyses to make meaningful associations between genes and diseases.
Regeneron Collaborates with TriNetX to Access De-identified Electronic Health Records of 300 Million Patients, 2 Apr 2026
Our lab technicians, data scientists and bioinformaticians collect and analyze large amounts of data using cloud technology to simultaneously look at genes, proteins, health records and more.
The Regeneron Scientific Journey (story), 9 Jun 2026
RGC leverages organoid models, siRNA, and CRISPR knockout models to validate genetic associations that lead to new therapeutic targets. ... These efforts at RGC have led to the identification of more than 40 novel genetic targets.
Regeneron 2025 Annual Report incl. Form 10-K FY2025, 4 Feb 2026, p. 22

Commitments made public in the last 12 months: 0

None identified in the reviewed sources.

Prior 12 months: 0. Search coverage: partial.

R&D roles open on 6 Oct 2026: 3

Technology named in these postings

Asked for as experience: Claude

Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Regeneron lists every source.

Astellaslive
Priority 6 / Delivery 7
Observed activity: 1 new · 2 roles

Priority 6: what the company says

A key partnership is our participation in Tokyo-1 ... This initiative utilizes the Tokyo-1 GPU supercomputer to accelerate our research in molecular simulation and AI-based molecular design
Integrated Report 2025 (FY2024, English), 31 Oct 2025, p. 62
in drug discovery research, we aim to accelerate the development of biopharmaceuticals and improve productivity, not only through NVIDIA's AI-powered supercomputing for small molecule drug design that has already been implemented
Astellas R&D Day event transcript, 31 March 2026, 31 Mar 2026, p. 19
Strategic investments in AI will help us improve speed, quality and ... decision-making across R&D ... Research ... Human-in-the-Loop platform, an AI ... and robotics integrated system to optimize drug candidates ... NVIDIA-powered supercomputing to ... dramatically accelerate early-stage ... drug discovery
Astellas R&D Day presentation, 31 March 2026, 31 Mar 2026, p. 21

Delivery 7, live: what it shows running

It also includes automated synthesis and assay systems using robots, and tools ... for automatically creating structure-activity relationship (SAR) tables ... The platform also ... incorporates the ability to remotely monitor the operation of the robots
Integrated Report 2025 (FY2024, English), 31 Oct 2025, p. 61
Astellas has been ahead of the curve, integrating AI into its drug development processes since 2019. The company's innovative "Human-in-the-Loop" platform is central to this effort
Integrated Report 2025 (English), 31 Oct 2025, p. 61
in drug discovery research, we aim to accelerate the development of biopharmaceuticals and improve productivity, not only through NVIDIA's AI-powered supercomputing for small molecule drug design that has already been implemented
Astellas R&D Day event transcript, 31 March 2026, 31 Mar 2026, p. 19

Commitments made public in the last 12 months: 1

Prior 12 months: 0. Search coverage: partial.

R&D roles open on 6 Oct 2026: 2

Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Astellas lists every source.

Sanofiscaled
Priority 6 / Delivery 6
Observed activity: 6 new · 3 roles

Priority 6: what the company says

3) Accelerate efficiency ... AI and data science are already supporting our teams in areas such as accelerating drug discovery
Sanofi Annual Report on Form 20-F 2025, 17 Feb 2026, p. 28
organized around four key priorities: 1) focus on growth; 2) lead with innovation; 3) accelerate efficiency; and 4) reinvent how we work
Sanofi Annual Report on Form 20-F 2025, 17 Feb 2026, p. 27
We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and creating compelling growth.
Sanofi Annual Report on Form 20-F 2025, 17 Feb 2026, p. 26

Delivery 6, scaled: what it shows running

Digital ... In R&D: ... 90% targets in the pipeline now being credentialed using our data and AI systems
Sanofi Annual Report on Form 20-F 2025, 17 Feb 2026, p. 137
100% small and large molecule drug design efforts now supported by AI/ML methods, doubling molecular throughput of research teams
Sanofi Annual Report on Form 20-F 2025, 17 Feb 2026, p. 137
our Target Discovery engines have delivered seven novel drug targets in just one year
Sanofi Annual Report on Form 20-F 2025, 17 Feb 2026, p. 28

Commitments made public in the last 12 months: 6

Prior 12 months: 4. Search coverage: partial.

R&D roles open on 6 Oct 2026: 3

Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Sanofi lists every source.

Amgenlive
Priority 6 / Delivery 4
Observed activity: 2 new · 21 roles

Priority 6: what the company says

Putting AI at the Heart of Drug Discovery ... Amgen is working toward using artificial intelligence and machine learning to shorten that timeline and raise the odds of success.
Amgen 2025 Annual Report: Letter to Shareholders and Form 10-K, 18 Mar 2026, p. 4
making the following changes effective June 1, 2026 ... will serve as executive vice president, Research and Development, Artificial Intelligence and Data.
Amgen Announces Retirement of David M. Reese, EVP and Chief Technology Officer (organizational changes), 22 Apr 2026
highlights the company's continued investment in scientific research, artificial intelligence in drug discovery, and advanced manufacturing.
Amgen Ranks #4 on Forbes' Most Innovative Large Companies List, 22 Sep 2026

Delivery 4, live: what it shows running

Amgen has developed an integrated ... generative loop, where AI and automation continuously refine each other.
Bio Meets Tech: How Amgen is Designing the Medicines of Tomorrow, 2 Dec 2025
Amgen's AI platforms help identify genetically validated targets, generate novel proteins and predict how drug candidates will perform before they reach the lab.
Amgen 2025 Annual Report: Letter to Shareholders and Form 10-K, 18 Mar 2026, p. 4
Head's team applies protein and chemistry language models and other AI-enabled design approaches to drug discovery
Amgen's Approach to AI-Enabled Clinical Development, 20 May 2026

Commitments made public in the last 12 months: 2

Prior 12 months: 0. Search coverage: partial.

R&D roles open on 6 Oct 2026: 21

and 15 more in the company brief.

Technology named in these postings

Asked for as experience: Docker, AWS, Hugging Face, Databricks, MLflow, Kubernetes

Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Amgen lists every source.

BayerProvisional
Priority 6 / Delivery 4
Observed activity: 3 new · 5 roles

Priority 6: what the company says

"Our ambition is to leverage AI to increase R&D productivity by 40 percent by 2030," said Sai Jasti, Senior Vice President, Head of Data Science & Artificial Intelligence, Bayer Pharmaceuticals R&D.
Bayer's strongest-ever pharma portfolio and promising pipeline drive future growth (Pharma Media Day 2026, News Release 2026-0056e), 1 Apr 2026, p. 12
By integrating AI platform architecture with anonymized ... data, our data scientists are empowered to maximize our in-house biologics portfolio, validate AI models, and scale solutions, thereby ultimately speeding up drug discovery.
Bayer's strongest-ever pharma portfolio and promising pipeline drive future growth (Pharma Media Day 2026, News Release 2026-0056e), 1 Apr 2026, p. 12
Through this acquisition, Bayer subsidiary Vividion Therapeutics Inc. is expanding its capabilities in terms of proprietary methods for computer-based genomic screening. ... Bayer paid an upfront consideration of around €19 million to acquire Tavros.
Bayer Annual Report 2025 (entire report PDF), 4 Mar 2026, p. 294

Delivery 4, live: what it shows running

Combining the Tavros platform with Vividion’s chemoproteomics expertise and capabilities continues to greatly enhance Vividion’s efforts to generate potential best- and first-in-class drug targets across oncology and immunology.
Bayer Annual Report 2025 (entire report PDF), 4 Mar 2026, p. 47
Following a successful proof of concept, Bayer selected Cradle as its best suited partner from among several vendors.
Bayer and Cradle enter collaboration to enhance AI-enabled antibody discovery and optimization (News Release 2026-0009e), 7 Jan 2026, p. 2
entered a three-year strategic collaboration to deploy Cradle's scientific AI software platform for protein engineering ... Bayer will integrate the generative AI platform into existing R&D workflows to enhance lead generation and optimization across its therapeutic antibody pipeline.
Bayer and Cradle enter collaboration to enhance AI-enabled antibody discovery and optimization (News Release 2026-0009e), 7 Jan 2026, p. 1

Commitments made public in the last 12 months: 3

Prior 12 months: 1. Search coverage: partial.

R&D roles open on 6 Oct 2026: 5

Provisional: a published company document could not be read in full, so these scores may change. Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Bayer lists every source.

GSKlive
Priority 6 / Delivery 4
Observed activity: 3 new · 2 roles

Priority 6: what the company says

At every step of the R&D process, we are using data tech, including AI, and platform technologies to be faster, more effective and more predictive in discovering and developing innovative medicines and vaccines.
GSK Annual Report 2025, 5 Mar 2026, p. 5
Our AI-powered, end-to-end oligonucleotide platform, 'Oligopolis', which incorporates the Elsie platform we acquired in 2024, is redefining research in chemistry and biology. The platform automates cycles of design, synthesis and testing
GSK Annual Report 2025, 5 Mar 2026, p. 34
GSK announced that it had acquired Elsie Biotechnologies, a San Diego-based private biotechnology company dedicated to unlocking the full potential of oligonucleotide therapeutics, for a total consideration of up to US$51 million
GSK Annual Report 2025, 5 Mar 2026, p. 245

Delivery 4, live: what it shows running

Our digital chemistry platform uses AI/machine learning (ML) and automation to accelerate design-build-test cycles in small-molecule discovery.
GSK Annual Report 2025, 5 Mar 2026, p. 34
Our AI-powered, end-to-end oligonucleotide platform, 'Oligopolis', which incorporates the Elsie platform we acquired in 2024, is redefining research in chemistry and biology. The platform automates cycles of design, synthesis and testing
GSK Annual Report 2025, 5 Mar 2026, p. 34
GSK uses these AI methods to compare expression data from healthy lung tissue with samples from COPD patients
Mapping disease at the cellular level: A single-cell revolution in drug discovery (Behind the Science), 12 Dec 2025

Commitments made public in the last 12 months: 3

Prior 12 months: 2. Search coverage: partial.

R&D roles open on 6 Oct 2026: 2

Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for GSK lists every source.

Merck KGaAlive
Priority 6 / Delivery 4
Observed activity: 1 new · 3 roles

Priority 6: what the company says

we also use it internally in our Healthcare business sector in early stages of drug discovery. Our AI in drug discovery program will accelerate the discovery of new and better drug candidates
2025 Annual Report of Merck KGaA, Darmstadt, Germany (2025-Q4-Report-NA.pdf), 5 Mar 2026, p. 41
successfully launch a state-of-the-art high-performance computer in Munich, Germany, designed to accelerate innovation across the three business sectors ... streamline drug discovery processes in its Healthcare business sector
one-HPC: High-performance computer launched with Lenovo and Equinix, 20 Nov 2025
RDKit helps our research and development scientists within our Healthcare business sector ... said Arvind Rajpal, Head of Discovery & Development Technologies at Research and Development within the Healthcare business sector of Merck KGaA, Darmstadt, Germany
RDKit conference with more than 300 participants (news release), 21 Sep 2026

Delivery 4, live: what it shows running

AIDDISON™, our generative AI-powered active ingredient discovery platform. In addition to external commercialization, we also use it internally in our Healthcare business sector in early stages of drug discovery.
2025 Annual Report of Merck KGaA, Darmstadt, Germany (2025-Q4-Report-NA.pdf), 5 Mar 2026, p. 41
Predictive Modeling Platform , a tool for AI-driven design of drug-like molecules for the Healthcare business sector, recently recognized with an in-house award
RDKit conference with more than 300 participants (news release), 21 Sep 2026
RDKit helps our research and development scientists within our Healthcare business sector turn chemical data into AI-ready representations and actionable insights for faster, better-informed molecular design.
RDKit conference with more than 300 participants (news release), 21 Sep 2026

Commitments made public in the last 12 months: 1

Prior 12 months: 1. Search coverage: partial.

R&D roles open on 6 Oct 2026: 3

Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Merck KGaA lists every source.

Johnson & Johnsonlive
Priority 5 / Delivery 4
Observed activity: 4 new · 10 roles

Priority 5: what the company says

says Justin Scheer, Vice President, In Silico Discovery, Innovative Medicine R&D, Johnson & Johnson ... Using our highly sophisticated AI, built on in-house data, we aim to accelerate the delivery of medicines
6 ways Johnson & Johnson is using AI to help advance healthcare, 8 Apr 2026
Once promising disease targets are identified, Johnson & Johnson is then leveraging AI to help discover molecules that could interact with the target.
6 ways Johnson & Johnson is using AI to help advance healthcare, 8 Apr 2026
By combining data, AI and machine learning (ML), and advanced computing with our scientific expertise, Johnson & Johnson is setting a new pace for discovering life-changing treatments for patients in need.
Artificial Intelligence - advancing healthcare from New Jersey to the world, 4 Sep 2026

Delivery 4, live: what it shows running

Johnson & Johnson is then leveraging AI to help discover molecules that could interact with the target. ... The company is doing this through its own state-of-the-art technologies, as well as in partnership with external collaborators.
6 ways Johnson & Johnson is using AI to help advance healthcare, 8 Apr 2026
So in molecular design in discovery, it's shortening the time from hit to lead. So we can do things faster.
Johnson & Johnson at Bernstein Strategic Decisions Conference (transcript), 27 May 2026, p. 7
So we have a number of examples of oral medicines that we are getting into humans much faster than we were able to do pre utilizing AI. ... we are clearly using it, and it's already ongoing.
Johnson & Johnson at Bernstein Strategic Decisions Conference (transcript), 27 May 2026, p. 8

Commitments made public in the last 12 months: 4

Prior 12 months: 2. Search coverage: partial.

R&D roles open on 6 Oct 2026: 10

and 4 more in the company brief.

Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Johnson & Johnson lists every source.

MSDlive
Priority 5 / Delivery 4
Observed activity: 4 new · 3 roles

Priority 5: what the company says

The collaboration builds on Merck's broader investments in AI/ML-enabled discovery, spanning computational or spatial biology, AI foundation models and real-world data
Merck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine, 18 Feb 2026
Merck's ambition to harness AI-enabled virtual cell technologies to enhance disease understanding, improve target identification and drive early development decisions
Merck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine, 18 Feb 2026
We also use data science, AI, and machine learning ... (ML) to help overcome bottlenecks in discovery, research, and development.
Purpose for Progress Impact Report 2025/2026, 18 Aug 2026, p. 22

Delivery 4, live: what it shows running

KERMT isn't just helping our researchers; as an open-source model, its code is available to the whole scientific community.
Our AI model KERMT is helping to advance drug discovery (story), 19 Mar 2026
We recently developed two foundation models which uncover patterns in disease to find better drug targets, allow faster molecular design and rapidly test small molecules
5 ways we're transforming artificial intelligence into impact (story), 9 Jan 2026
Developed in collaboration with Nvidia, KERMT, pronounced "Kermit" and short for Kinetic GROVER Multi-Task, is a deep-learning computer model trained on more than 11 million molecules.
Our AI model KERMT is helping to advance drug discovery (story), 19 Mar 2026

Commitments made public in the last 12 months: 4

Prior 12 months: 2. Search coverage: partial.

R&D roles open on 6 Oct 2026: 3

Technology named in these postings

Asked for as experience: Amazon Web Services (AWS), Claude Code, Databricks, Docker, GitHub Actions, Google Cloud Platform (GCP), MLflow, Python, PyTorch

Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for MSD lists every source.

Modernalive
Priority 5 / Delivery 4
Observed activity: 1 new · 4 roles

Priority 5: what the company says

Power innovation through our Scientific Intelligence Engine Harness data, AI/ML, automation, and robotics to accelerate discovery and continuously improve how we work
Moderna Science Day 2026 presentation, 25 Jun 2026, p. 116
Our AI strategy turns platform data and biological insight into faster innovation
Moderna Science Day 2026 presentation, 25 Jun 2026, p. 10
Across Moderna, we are building what we call our Scientific Intelligence Engine—a system that combines data, AI and machine learning, automation, and robotics to accelerate discovery and improve how we work.
Building Moderna's Next Decade of Growth (Stephane Bancel, Science Day post), 25 Jun 2026

Delivery 4, live: what it shows running

At the research stage, our digital and AI infrastructure allows our scientists to design novel mRNA constructs, use AI algorithms to optimize them and order them from our high throughput preclinical scale production line.
Moderna Form 10-K for fiscal year ended 31 December 2025, 20 Feb 2026, p. 26
Lucy is at the heart of Moderna's scientific intelligence engine. Lucy connects everything that we've built in AI, automation, experimentation, and data into a continuously improving learning system.
Moderna Science Day transcript (LSEG StreetEvents), 25 Jun 2026, p. 25
We do have an ongoing program to try and improve this algorithm. In fact, we're using artificial intelligence to try to develop the next algorithm.
Q2 2026 Moderna earnings call transcript, 31 Jul 2026, p. 9

Commitments made public in the last 12 months: 1

Prior 12 months: 0. Search coverage: partial.

R&D roles open on 6 Oct 2026: 4

Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Moderna lists every source.

UCBlive
Priority 5 / Delivery 4
Observed activity: 3 new · 1 role

Priority 5: what the company says

UCB has acquired the Patient Insight Business of IMIDomics ... which applies advanced biostatistics, machine learning, and AI to uncover new therapeutic targets, responder biomarkers
UCB announces acquisition of IMIDomics' Patient Insight Business, 1 May 2026
Patient Insight Business enhances UCB’s ability to identify novel drug targets, discover responder biomarkers, and design molecularly informed patient stratification approaches
UCB announces acquisition of IMIDomics' Patient Insight Business, 1 May 2026
On 1 May 2026, the Group acquired the Patient Insight Business of IMIDomics. The acquisition provides UCB with direct access to one of the most advanced, deeply curated human datasets in immunology
UCB 2026 Half-Year Financial Report, 30 Jul 2026, p. 29

Delivery 4, live: what it shows running

Our collaborations with Schrödinger are also integrating advanced modeling and computational design, to accelerate discovery and enhance data quality across key R&D pillars such as multi-specific medicines and digital antibody engineering.
UCB Integrated Annual Report 2025, 26 Feb 2026, p. 19
On 1 May 2026, the Group acquired the Patient Insight Business of IMIDomics. The acquisition provides UCB with direct access to one of the most advanced, deeply curated human datasets in immunology
UCB 2026 Half-Year Financial Report, 30 Jul 2026, p. 29
In January 2025, UCB entered into a license agreement on XtalFold™, a biologics AI platform developed by Ailux Biologics, a division of XtalPi. UCB will leverage XtalFold™ for the discovery and engineering of biologics.
UCB Integrated Annual Report 2025, Feb 2026, p. 180

Commitments made public in the last 12 months: 3

Prior 12 months: 1. Search coverage: partial.

R&D roles open on 6 Oct 2026: 1

Technology named in these postings

Asked for as experience: Python, R

Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for UCB lists every source.

Boehringer Ingelheimbuild underway
Priority 5 / Delivery 3
Observed activity: 8 new · 11 roles

Priority 5: what the company says

Anticipated £150M investment over 10 years as part of Boehringer's commitments in AI across R&D, with the first 50 AI experts in place by end of 2027
Boehringer Ingelheim expands investment in computational innovation with new AI Accelerator in UK Knowledge Quarter, 20 Apr 2026
Computational science is central to our innovation strategy.
Computational Innovation (UK corporate page), 7 Apr 2026
Computational Innovation identifies and builds confidence in new therapeutic concepts and increases the likelihood of success across our portfolio.
Partnering in Computational Innovation flyer (June 2026), 18 Jun 2026, p. 1

Delivery 3, build underway: what it shows running

Boehringer Ingelheim today announced the expansion of its global Computational Innovation footprint with the launch of a new center for AI and machine learning in King's Cross, London, UK
Boehringer Ingelheim expands investment in computational innovation with new AI Accelerator in UK Knowledge Quarter, 20 Apr 2026
Computational Innovation now has locations in Austria, Germany, UK and USA specializing in AI, machine learning, human genetics, and computational biology.
Boehringer Ingelheim expands investment in computational innovation with new AI Accelerator in UK Knowledge Quarter, 20 Apr 2026
Molecule design: Leveraging AI to help create high-quality molecules faster.
Computational Innovation (UK corporate page), 7 Apr 2026

Commitments made public in the last 12 months: 8

Prior 12 months: 1. Search coverage: partial.

R&D roles open on 6 Oct 2026: 11

and 5 more in the company brief.

Technology named in these postings

Asked for as experience: Python

Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Boehringer Ingelheim lists every source.

AbbViefunded or contracted
Priority 5 / Delivery 2
Observed activity: 3 new · 6 roles

Priority 5: what the company says

Through our areas of innovation, which include data convergence, artificial intelligence (AI), genetic medicine and genomics, patient-focused disease medicine and therapeutic modalities, we are leveraging powerful tools in order to accelerate discovery
AbbVie 2025 ESG Action Report, No printed date. Its content dates it to 23 Mar 2026 or later, and we read it on 6 Oct 2026, p. 17
AI: We are integrating AI into our R&D processes to support improved drug discovery and development. We use AI to extract knowledge from data across our entire pipeline, from enabling more efficient molecule property prediction
AbbVie 2025 ESG Action Report, No printed date. Its content dates it to 23 Mar 2026 or later, and we read it on 6 Oct 2026, p. 18
Under the terms of the collaboration, Iambic will receive an upfront payment and is eligible to receive success-based milestone payments and tiered royalties on net sales from products generated from the collaboration.
AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery, 21 Sep 2026

Delivery 2, funded or contracted: what it shows running

today announced a multi-year collaboration to accelerate the discovery and development of small molecule therapies with first-in-class and best-in-class potential across immunology, neuroscience and oncology
AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery, 21 Sep 2026
Under the terms of the collaboration, Iambic will receive an upfront payment and is eligible to receive success-based milestone payments and tiered royalties on net sales from products generated from the collaboration.
AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery, 21 Sep 2026
AI: We are integrating AI into our R&D processes to support improved drug discovery and development. We use AI to extract knowledge from data across our entire pipeline, from enabling more efficient molecule property prediction
AbbVie 2025 ESG Action Report, No printed date. Its content dates it to 23 Mar 2026 or later, and we read it on 6 Oct 2026, p. 18

Commitments made public in the last 12 months: 3

Prior 12 months: 2. Search coverage: partial.

Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for AbbVie lists every source.

Novartisclaimed
Priority 5 / Delivery claimed
Observed activity: 3 new · 8 roles

Priority 5: what the company says

Our Novartis R&D leaders, Fiona Marshall ... have defined a clear strategy for how these technological advances should be integrated from end-to-end, across the R&D continuum.
Story: Smarter decisions at scale: How Novartis is using AI to advance R&D, 28 Jul 2026
Scaling AI across the value chain to unlock productivity and performance ... Target Discovery Engine ... Small molecule GenChem and optimization
Meet Novartis Management 2025 CEO presentation (investor event, London), 20 Nov 2025, p. 29

Delivery claimed, claimed: what it shows running

This is playing out in focused initiatives across Novartis R&D: Target identification and validation: AI models can integrate evidence from human genetic and multi-omic datasets
Story: Smarter decisions at scale: How Novartis is using AI to advance R&D, 28 Jul 2026
Reviewed AI use case on “New Target Identification”, “Driving Translation through Data Science and AI”, “Present and Future of AI Augmented Chemistry”, and “AI/ML in Biologics”
Novartis Annual Report 2025 (Form 20-F format; AR and 20-F counted as one source), 4 Feb 2026, p. 125
These efforts are shifting how teams work so they’re spending less time sifting through data and more time on creative iteration and decision-making.
Story: Smarter decisions at scale: How Novartis is using AI to advance R&D, 28 Jul 2026

Commitments made public in the last 12 months: 3

Prior 12 months: 5. Search coverage: partial.

Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Novartis lists every source.

Pfizerbuild underway
Priority 5 / Delivery claimed
Observed activity: 5 new · 4 roles

Priority 5: what the company says

Our 2026 key priorities are: ... Scale AI across our business.
Pfizer 2025 Form 10-K, 26 Feb 2026, p. 10
In addition, we are scaling AI across R&D, manufacturing, commercial and patient engagement to improve productivity and accelerate innovation.
Pfizer 2025 Form 10-K, 26 Feb 2026, p. 10
Build an end-to-end AI-native R&D organization
Q2 2026 earnings charts, 4 Aug 2026, p. 9

Delivery claimed, build underway: what it shows running

To meet the growing AI demand, over the next two years, we are expanding to more than 1,200 GPUs, largely driven by R&D application of AI.
Q4 2025 earnings call prepared remarks, 3 Feb 2026, p. 3
We are embedding AI into each functional line in R&D.
Q1 2026 earnings call prepared remarks, 5 May 2026, p. 5
It's going to be by deploying AI, which already happened in 2025 with excellent results that creates significant productivity gains. This is where we are reducing the cost of R&D.
Q4 2025 Pfizer Inc Earnings Call transcript (LSEG edited, company-hosted), 3 Feb 2026, p. 14

Commitments made public in the last 12 months: 5

Prior 12 months: 3. Search coverage: partial.

Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Pfizer lists every source.

Takedafunded or contracted
Priority 4 / Delivery 2
Observed activity: 5 new · 16 roles

Priority 4: what the company says

We seek to achieve a foundational shift that embeds AI into every stage of drug discovery, redesigning workflows to include automated, data-driven, predictive processes that accelerate innovation.
Takeda Annual Report on Form 20-F for FY2025 (year ended 31 March 2026), 17 Jun 2026, p. 25
By using advanced models to predict how molecules will behave, we can identify high-quality candidates earlier and rapidly optimize their design.
Takeda 2026 Annual Integrated Report (FY2025), 27 Jun 2026, p. 8
Through bold investments in digital, data and AI-driven capabilities, our teams are delivering for patients at speed and scale.
Takeda 2026 Annual Integrated Report (FY2025), 27 Jun 2026, p. 8

Delivery 2, funded or contracted: what it shows running

Iambic Therapeutics U.S. Cross-therapeutic area discovery research alliance to leverage Iambic’s computational-driven discovery engine
Takeda Annual Report on Form 20-F for FY2025 (year ended 31 March 2026), 17 Jun 2026, p. 49
By using advanced models to predict how molecules will behave, we can identify high-quality candidates earlier and rapidly optimize their design.
Takeda 2026 Annual Integrated Report (FY2025), 27 Jun 2026, p. 8

Commitments made public in the last 12 months: 5

Prior 12 months: 1. Search coverage: partial.

R&D roles open on 6 Oct 2026: 16

and 10 more in the company brief.

Technology named in these postings

Named as in use: SAIL (TetraScience programme), TetraScience

Asked for as experience: Python

Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Takeda lists every source.

Gileadclaimed
Priority 2 / Delivery claimed
Observed activity: 0 new · 2 roles

Priority 2: what the company says

Gilead will build and maintain leadership capabilities to govern AI responsibly while applying these powerful new tools to support drug discovery, improve the employee experience and expedite responsible business reporting efforts.
2025 Responsible Business and Impact Report, 21 Apr 2026, p. 10
Brings Together Oncology, Inflammation and Research Data Science Teams to Foster Scientific Collaboration
Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines, 8 Sep 2026

Delivery claimed, claimed: what it shows running

today celebrated the opening of its 182,000-square-foot Research Center at its Foster City headquarters, expanding capabilities in oncology, inflammation and research data science
Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines, 8 Sep 2026
By co-locating key research disciplines and expanding our data science capabilities, we are strengthening the infrastructure needed to accelerate discovery and advance meaningful innovations.
Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines, 8 Sep 2026

Commitments made public in the last 12 months: 0

None identified in the reviewed sources.

Prior 12 months: 1. Search coverage: partial.

R&D roles open on 6 Oct 2026: 2

Technology named in these postings

Asked for as experience: Python

Showing up to three quotes for each score. Observed activity is a count of public signals, not a score, and search coverage varies by company. The full account brief for Gilead lists every source.

No eligible company disclosure identified for this theme in the reviewed sources and period

This is not a finding that these companies are inactive. Their account briefs show what we searched and any related activity we recorded as context.

Report new information

Tell us about a public source we missed, or a correction to a company's entry. We only use information anyone can read: company releases, filings, results materials, partner announcements and similar. Nothing you send appears on the radar automatically. We check every report and include what holds up in the next quarterly refresh.

Privacy notice

How the scores work. Scores follow Ortent's rubric, summarised on the method page. Only evidence dated inside the window counts. A page with no printed date counts only when its own content dates it, and the quote shows that range. Job adverts, vendor marketing and private knowledge never count towards a score; job adverts appear only as observed activity. For this radar, process and CMC development are grouped with manufacturing and excluded from the research-lab theme. The full method and a brief for each company are on the method page.

Status. Ortent built and reviewed this research; it has not been independently validated. The radar does not predict who will buy, and it does not measure how mature a company's operations are.

Disclosure. Andrew Wyatt, Ortent's principal, was Chief Growth Officer at Sapio Sciences, a lab software company, until April 2026. He has no current relationship with, or financial interest in, Sapio or any other supplier.

// GET IN TOUCH

Clarity when it counts.

For a board, advisory or fractional engagement, or a working call on the next stage, send a note. Thirty minutes is usually enough to test fit.

Request a 30-minute intro call